CONSERVE is a long-term safety and efficacy study for those patients who wish to continue on Coversin treatment following completion of a clinical trial. All seven patients that completed the COBALT trial opted to be enrolled into the CONSERVE study.
As of June 30, 2018, these patients have been receiving Coversin subcutaneously for between 9 to 18 months in the aggregate (factoring in time spent on COBALT and CONSERVE), with five patients injecting once-daily and two injecting twice daily.
To date, there have been no drug-related serious adverse events reported and patients are self-administering. Six of the former COBALT patients were on 45 mg Coversin and one patient was on 30 mg Coversin.